Evidence map›Paper›PMID 38982470›Full record

ArticleJournal of inflammation (London, England)2024

Protective and curative effects of unconjugated bilirubin on gene expression of LOX-1 and iNOS in the heart of rats receiving high-fat diet and low dose streptozotocin: a histomorphometric approach.

Mohammad Hasan Maleki, Omid Vakili, Ramin Tavakoli, Elham Nadimi, Zahra Noori, Motahareh Taghizadeh, Amirreza Dehghanian, Lobat Tayebi, Sayed Mohammad Shafiee

Abstract read
In one paragraph

Article in Journal of inflammation (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad Hasan MalekiDepartment of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0000-0002-0095-4264
Omid VakiliAutophagy Research Center, Department of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0000-0002-9103-872X
Ramin TavakoliDepartment of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Elham NadimiHistomorphometry and Stereology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0000-0003-0153-2650
Zahra NooriDepartment of Anatomical Sciences, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0009-0009-0039-2343
Motahareh TaghizadehDepartment of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0000-0003-0256-4910
Amirreza DehghanianTrauma Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0000-0003-0360-7468
Lobat TayebiMarquette University School of Dentistry, Milwaukee, WI, 53233, USA.
Sayed Mohammad ShafieeAutophagy Research Center, Department of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. shafieem@sums.ac.ir.ORCID http://orcid.org/0000-0002-9221-2267

Funding

Supplement: Development of an Integrated 3D Human Osteo-Mucosal ModelR15DE027533 · NIDCR · MARQUETTE UNIVERSITY · PI TAYEBI, LOBAT · 2018 to 2021
$816k
Vascularization of critical-sized craniomaxillofacial defectsR56DE029191 · NIDCR · MARQUETTE UNIVERSITY · PI TAYEBI, LOBAT · 2021 to 2021
$363k
NIDCR NIH HHS R15 DE027533NIDCR NIH HHS R56 DE029191Vice-Chancellor for Research, Shiraz University of Medical Sciences 28528
6 · The paper itself

Abstract

backgroundAtherosclerosis is a chronic inflammatory condition affecting the large arteries and is a major cause of cardiovascular diseases (CVDs) globally. Increased levels of adhesion molecules in cardiac tissue serve as prognostic markers for coronary artery occlusion risk. Given the antioxidant properties of bilirubin and its inverse correlation with atherosclerosis, this study aimed to assess the beneficial effects of bilirubin on atherosclerotic indices and heart structure in high-fat diet-fed diabetic rats with atherosclerosis.

methodsAtherosclerosis was induced in three out of five groups of adult male Sprague Dawley rats through a 14-week period of high-fat diet (HFD) consumption and a single low dose of streptozotocin (STZ) (35 mg/kg). The atherosclerotic rats were then treated with intraperitoneal administration of 10 mg/kg/day bilirubin for either 6 or 14 weeks (treated and protected groups, respectively), or the vehicle. Two additional groups served as the control and bilirubin-treated rats. Subsequently, the mRNA expression levels of vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), lectin-like LDL receptor 1 (LOX-1), and the inducible nitric oxide synthase (iNOS) were analyzed using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Histopathological and stereological analyses were performed to assess changes in the heart structure.

resultsBilirubin significantly decreased the expression of VCAM-1, ICAM-1, LOX-1, and iNOS genes in the treated group. Moreover, bilirubin mitigated pathological damage in the left ventricle of the heart. Stereological analysis revealed a decrease in the left ventricle and myocardium volume, accompanied by an increase in vessel volume in rats treated with bilirubin.

conclusionThese findings demonstrate that mild hyperbilirubinemia can protect against the progression of atherosclerosis and heart failure by improving lipid profile, modulating adhesion molecules, LOX-1, and iNOS gene expression levels.

Indexed as

AtherosclerosisBilirubinCell adhesion moleculesHeartHigh fat dietOxidative stress

Identifiers

PMID38982470
PMCPMC11234610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.